Economic evaluation reveals substantial variation in coverage criteria for atopic dermatitis medications across commercial plans, indicating potential barriers to specialized skin disease treatment.
This economic evaluation examines the diagnostic threshold, step therapy, and prescriber requirements from commercial health plans for covering 7 US Food and Drug Administration–approved atopic dermatitis medications.
No takes yet. Share an insight, caveat, or question.
Brennan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: